Promega Corporation

pmirGLO Dual-Luciferase miRNA Target Expression Vector

The pmirGLO Vector is designed to quantitatively evaluate microRNA (miRNA) activity by the insertion of miRNA target sites downstream or 3´ of the firefly luciferase gene (luc2). Firefly luciferase is the primary reporter gene; reduced firefly luciferase expression indicates the binding of endogenous or introduced miRNAs to the cloned miRNA target sequence. This vector is based on Promega dual-luciferase technology, with firefly luciferase (luc2) used as the primary reporter to monitor mRNA regulation and Renilla luciferase (hRluc-neo) acting as a control reporter for normalization and selection.

...

Expand to Read More »

  • Share
  • Print
  • Email
  • Prices valid for customers of Promega France only
Product Size Conc. Catalog # *List Price Order QTY Add to Cart

pmirGLO Dual-Luciferase miRNA Target Expression Vector

Close Window

pmirGLO Dual-Luciferase miRNA Target Expression Vector

 Components

  • Oligo Annealing Buffer

    C838A1 x 1ml
  • pmirGLO Vector

    E133A1 x 20μg
Close Window
  • This product can be added to a

  • Helix Freezer

This product is available through the Promega Helix onsite stocking program in a –20°C Helix Freezer. The program offers numerous convenient solutions to meet your lab's needs. Helix Freezers are available in two sizes: 5.7 cubic ft. or 9.7 cubic ft.


Click here to learn more about the Helix Collection »


Already a Helix Customer?

Request to add this product to your Helix »


20μg
- E1330 € 421,00 Add to cart


You Also May Be Interested In

GenBank®/EMBL Accession Number

pmirGLO Vector Accession Number FJ376737; pmirGLO Vector sequence text file.

Storage Conditions

Store at –20°C.

For product intended use please see Patents & Disclaimers tab.

pmirGLO Vector. Figure 1. pmirGLO Vector.
Mechanism of action of the pmirGLO Vector.Figure 2. Mechanism of action of the pmirGLO Vector.
Normalized luciferase activity using the pmirGLO Vector with an mi-R21 target sequence.Figure 3. Normalized luciferase activity using the pmirGLO Vector with an mi-R21 target sequence.

Use Restrictions

E1330 For Research Use Only. Not for Use in Diagnostic Procedures.

Patents - Disclaimers

E1330 BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE LABEL LICENSE. If the researcher is not willing to accept the terms of this label license, and the product is unused, Promega will accept return of the unused product and provide the researcher with a full refund.
Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for money or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene except that researchers may: (1) create fused gene sequences provided that the coding sequence of the resulting luciferase gene has no more than four deoxynucleotides missing at the affected terminus compared to the intact luciferase gene sequence, and (2) insert and remove nucleic acid sequences in splicing research predicated on the inactivation or reconstitution of the luminescence of the encoded luciferase. No other use or transfer of this product or derivatives is authorized without the prior express written consent of Promega. In addition, researchers must either: (1) use luminescent assay reagents purchased from Promega for all determinations of luminescence activity of this product and its derivatives; or (2) contact Promega to obtain a license for use of the product and its derivatives. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA. This label license relates to Promega patents and/or patent applications on improvements to the luciferase gene.

E1330 U.S. Pat. No. 5,670,356.

E1330 U.S. Pat. No. 8,008,006 and European Pat. No. 1341808.

E1330 The method of recombinant expression of Coleoptera luciferase is covered by U.S. Pat. Nos. 5,583,024, 5,674,713 and 5,700,673. A license (from Promega for research reagent products and from The Regents of the University of California for all other fields) is needed for any commercial sale of nucleic acid contained within or derived from this product.

Prefer a different language?

Your country is set to France. Your language is set to français. Please select the language that will best suit your needs:

This is correct, continue to site »

I need additional help

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.